Last updated: September 4, 2026
Peginterferon alfa-2b is a mature, declining biologic whose commercial value was built on hepatitis C treatment and later reduced by direct-acting antiviral therapies. Merck’s PEG-Intron franchise lost most of its market after 2014 as shorter, better-tolerated oral regimens replaced interferon-based therapy. The product has limited current commercial relevance in hepatitis C, no material biosimilar-driven growth, and a largely exhausted exclusivity position. Its remaining value depends on restricted clinical use, supply continuity, and potential niche applications rather than broad-market expansion.
What is peginterferon alfa-2b used for?
Peginterferon alfa-2b is a covalent conjugate of recombinant interferon alfa-2b and polyethylene glycol. Pegylation extends the drug’s half-life and permits less frequent dosing than unmodified interferon alfa-2b.
Historically, the principal indications were:
| Indication |
Commercial role |
| Chronic hepatitis C |
Primary historical market |
| Chronic hepatitis B in selected territories |
Limited or regional use |
| Adjuvant treatment of melanoma |
Marketed in the United States as Sylatron |
| Certain investigational oncology and infectious-disease uses |
No major commercial contribution |
PEG-Intron was used with ribavirin and, in some treatment settings, other antiviral agents for chronic hepatitis C. Sylatron was approved for adjuvant treatment of melanoma with microscopic or gross nodal involvement after definitive surgical resection.[1,2]
The product’s clinical disadvantages include flu-like adverse effects, depression and psychiatric toxicity, cytopenias, thyroid dysfunction, autoimmune effects, and the need for injectable administration. These limitations became commercially decisive once oral direct-acting antivirals reached the hepatitis C market.
How did the hepatitis C market change peginterferon alfa-2b revenue?
The financial trajectory has three distinct periods.
2001 to 2013: established specialty pharmaceutical franchise
PEG-Intron entered the United States hepatitis C market in 2001. At that time, pegylated interferon combined with ribavirin was the leading treatment platform for chronic hepatitis C. The product competed primarily with peginterferon alfa-2a, marketed as Pegasys by Roche.
Demand was supported by:
- Large diagnosed and untreated hepatitis C populations.
- Treatment courses lasting approximately 24 to 48 weeks.
- High specialist involvement and limited therapeutic alternatives.
- Reimbursement for combination antiviral therapy.
- Use in genotype-specific treatment protocols.
The commercial model was based on prolonged treatment duration and high annual patient throughput. PEG-Intron generated meaningful value for Schering-Plough and later Merck, although Merck’s public financial reporting generally did not provide a separate PEG-Intron revenue line. Sales were grouped within broader pharmaceutical or infectious-disease categories rather than reported as a standalone product.
2014 to 2016: rapid substitution by oral direct-acting antivirals
The introduction of highly effective oral direct-acting antiviral regimens changed treatment economics. Products such as Sovaldi, Harvoni, Viekira Pak, and later Epclusa offered cure rates generally above those associated with interferon-based therapy while avoiding interferon’s systemic toxicity.
The competitive effects were immediate:
| Market factor |
Effect on peginterferon alfa-2b |
| Oral dosing |
Reduced demand for injectable treatment |
| Shorter treatment courses |
Reduced volume per treated patient |
| Higher sustained virologic response rates |
Displaced interferon regimens |
| Better tolerability |
Reduced physician willingness to use PEG-Intron |
| Simplified treatment protocols |
Reduced specialist dependence |
| Falling DAA prices over time |
Improved payer access to replacement therapies |
The decline was structural rather than cyclical. Once patients, prescribers, and payers shifted to direct-acting antivirals, recovery of the interferon market became unlikely.
2017 onward: legacy and restricted-use market
After direct-acting antivirals became standard therapy, peginterferon alfa-2b became a legacy product. Its hepatitis C role was reduced to narrow circumstances, including historical retreatment protocols, treatment access limitations in selected countries, and situations in which newer therapies were unavailable or clinically unsuitable.
The United States market no longer provides a meaningful growth platform for PEG-Intron. Merck’s discontinuation and supply decisions have reduced commercial visibility, while the hepatitis C treatment standard has moved decisively to oral antiviral regimens.[3,4]
What is the current FDA regulatory status of peginterferon alfa-2b?
PEG-Intron received FDA approval for chronic hepatitis C in 2001. Sylatron received FDA approval in 2011 for adjuvant treatment of melanoma.[1,2]
The regulatory position is commercially complex:
- Peginterferon alfa-2b remains an FDA-recognized active ingredient with historical approved labeling.
- The original hepatitis C indication has been overtaken clinically by direct-acting antivirals.
- PEG-Intron and Sylatron have had limited or discontinued commercial availability in the United States.
- Product availability, rather than clinical efficacy alone, is a central current-market issue.
- The drug is not positioned as a first-line hepatitis C treatment in modern U.S. practice.
Peginterferon alfa-2b should not be confused with ropeginterferon alfa-2b, marketed as Besremi. Ropeginterferon alfa-2b is a different, longer-acting interferon product approved in the United States for polycythemia vera.[5] A positive commercial performance by Besremi does not create direct revenue for PEG-Intron or establish renewed demand for peginterferon alfa-2b.
What is the Orange Book status of peginterferon alfa-2b?
PEG-Intron’s original exclusivity position is effectively exhausted. The product was approved more than two decades ago, placing any original U.S. regulatory exclusivity and core patent protection well beyond their ordinary terms.
A practical Orange Book assessment is:
| Issue |
Assessment |
| Reference-product age |
Original U.S. approval in 2001 |
| New chemical entity exclusivity |
Expired |
| Biologic reference-product exclusivity |
Not a meaningful current barrier |
| Core composition protection |
Expected to be expired |
| Current commercial barrier |
Manufacturing, supply, and market access |
| Orange Book value |
Limited for blocking modern hepatitis C competition |
The Orange Book is designed primarily for approved drug products and patent certifications under the Hatch-Waxman framework. For a biologic such as peginterferon alfa-2b, the Biologics License Application framework and the Purple Book are more relevant to biological-product substitution and biosimilar analysis.[6,7]
Because PEG-Intron predates the modern biosimilar framework, its exclusivity profile does not resemble that of a recently approved biologic. The remaining commercial question is whether a sponsor can manufacture and register a reliable product at an acceptable cost, not whether the original sponsor can preserve a high-value patent moat.
What patents protect peginterferon alfa-2b?
The original patent estate likely included several protection layers:
- Interferon alfa-2b compositions.
- Polyethylene glycol conjugation chemistry.
- Defined pegylated interferon molecular-weight distributions.
- Pharmaceutical formulations.
- Manufacturing and purification processes.
- Methods for treating hepatitis C.
- Methods for treating melanoma.
The earliest protection around pegylated interferon alfa products dates from the 1990s and early 2000s. Those patents have reached or passed their ordinary expiration windows, including patent-term-adjustment periods in relevant cases.
Formulation patents
Formulation claims may have covered:
- Stabilized injectable solutions.
- Buffer and excipient combinations.
- Concentration ranges.
- Storage conditions.
- Prefilled syringes or delivery configurations.
These patents could have extended protection beyond the earliest composition claims, but they do not create a current high-value barrier comparable to a recently launched long-acting biologic. Formulation protection is especially weak where competing sponsors can use different excipient systems or container configurations.
Method-of-use patents
Historical method patents covered interferon treatment of hepatitis C and melanoma. Their present value is limited by:
- Expiration of early treatment-method claims.
- Replacement of interferon by direct-acting antiviral regimens.
- Reduced commercial demand for the covered indications.
- Potential limitations on enforceability where claims are no longer commercially material.
Manufacturing and process protection
Manufacturing know-how remains more relevant than expired composition patents. A new sponsor would need validated cell culture, purification, pegylation control, viral clearance, analytical characterization, and sterile filling. These requirements create cost and execution risk, but they are not equivalent to patent exclusivity.
How strong is the patent estate for peginterferon alfa-2b?
The patent estate is weak as a market-exclusion tool and moderate as a manufacturing barrier.
| Patent-estate category |
Current strength |
| Original active ingredient |
Low |
| Pegylation concept |
Low |
| Core therapeutic use |
Low |
| Formulation |
Low to moderate |
| Device and presentation |
Low |
| Manufacturing know-how |
Moderate |
| Regulatory and quality package |
Moderate |
| Brand recognition |
Low in hepatitis C; limited in oncology |
The strongest remaining barriers are operational. They include process reproducibility, product comparability, commercial-scale sterile manufacturing, quality control, and the economics of entering a small market. These barriers can deter competition even when patents do not.
Are there biosimilar or generic risks for peginterferon alfa-2b?
There is no meaningful small-molecule generic pathway because peginterferon alfa-2b is a biologic. A competing product would generally require a biologics pathway, potentially involving a biosimilar or interchangeable biosimilar application under the Public Health Service Act.
The commercial risk from a new biosimilar is limited by market size. A competitor would face:
- High analytical and manufacturing costs.
- A shrinking hepatitis C market.
- Uncertain demand from U.S. oncology use.
- Potentially weak payer incentives.
- Limited physician demand where newer therapies are preferred.
- Supply-chain and pharmacovigilance obligations.
A biosimilar could still be commercially viable in countries where interferon remains part of hepatitis treatment protocols or where DAA access is restricted. The competitive risk is therefore geographically uneven.
When does peginterferon alfa-2b lose exclusivity?
Peginterferon alfa-2b lost the practical value of its core exclusivity years ago. The relevant timeline is:
| Date or period |
Event |
| 2001 |
FDA approval of PEG-Intron for chronic hepatitis C |
| 2000s |
Peak commercial period for pegylated interferon in hepatitis C |
| 2011 |
FDA approval of Sylatron for adjuvant melanoma |
| 2013-2015 |
Rapid adoption of direct-acting antiviral therapies |
| 2014 onward |
Structural collapse in interferon-based hepatitis C demand |
| 2017 onward |
Legacy-product positioning and reduced commercial availability |
| Current period |
No meaningful original-patent barrier to competition |
A precise single “loss of exclusivity” date is less useful than the broader commercial conclusion: the market became noncompetitive with respect to interferon before the product’s practical value fully disappeared. Direct-acting antivirals destroyed demand even before all potential secondary protections became economically irrelevant.
Which companies challenged or competed with peginterferon alfa-2b?
The main historical competitor was Roche’s Pegasys, peginterferon alfa-2a. The more consequential competitors were not other interferons but direct-acting antiviral manufacturers.
| Company |
Product or platform |
Competitive effect |
| Roche |
Pegasys |
Direct peginterferon competitor |
| Gilead Sciences |
Sovaldi, Harvoni, Epclusa |
Major displacement of interferon |
| AbbVie |
Viekira Pak and later HCV products |
Accelerated oral-regimen substitution |
| Bristol Myers Squibb |
Daklinza |
Expanded non-interferon treatment options |
| Merck |
Zepatier |
Added oral DAA competition |
The competitive landscape shifted from brand-versus-brand competition to treatment-platform substitution. PEG-Intron did not lose primarily because of a lower-priced generic. It lost because physicians and payers adopted a more effective treatment architecture.
What is the financial trajectory of peginterferon alfa-2b?
Public companies have not consistently reported standalone PEG-Intron revenue, so a precise current revenue series is not available from issuer filings. The direction is clear:
- High-value specialty franchise before widespread DAA adoption.
- Rapid sales erosion after 2014.
- Loss of strategic importance within Merck’s portfolio.
- Residual revenue from legacy markets, limited oncology use, or remaining inventory.
- No credible basis for a return to prior peak economics.
The product’s revenue exposure is now low relative to Merck’s major oncology, vaccines, hospital, and immunology franchises. The commercial asset has shifted from growth product to portfolio-management issue.
Revenue sensitivity
| Driver |
Impact on financial trajectory |
| HCV diagnosis rates |
Low positive effect |
| DAA access restrictions |
Positive effect in limited markets |
| DAA price reductions |
Negative effect |
| Interferon tolerability |
Negative effect |
| Product discontinuation |
Negative effect |
| New indication approval |
Potentially positive but unproven |
| Biosimilar entry |
Negative price effect, but limited absolute exposure |
| Manufacturing scarcity |
Could support price but constrain volume |
What generic launch scenarios exist?
Scenario 1: No meaningful U.S. follow-on entry
This is the most commercially plausible outcome. The U.S. hepatitis C market no longer supports large-scale interferon demand, and the remaining indication base is too small to justify extensive development spending.
Scenario 2: Regional biosimilar entry
A sponsor could target countries where interferon remains used because of cost, reimbursement, or limited DAA access. Such an entrant would compete primarily on price and supply reliability.
Scenario 3: Niche oncology supply
A manufacturer could pursue limited supply for melanoma or other interferon-sensitive uses. This scenario would require a stable institutional customer base and reliable reimbursement. It would not restore the historical hepatitis C market.
Scenario 4: New indication development
A new indication could improve the product’s economics, but interferon’s toxicity and the availability of newer immune-modulating agents make a large expansion unlikely without strong clinical differentiation.
What patent litigation and settlement agreements affect peginterferon alfa-2b?
Peginterferon alfa-2b is not currently associated with a major active U.S. patent-litigation cycle comparable to recently launched biologics or high-revenue small molecules. The important historical commercial conflicts were more likely to involve competition between branded interferon products and regulatory or manufacturing issues than a current wave of Paragraph IV litigation.
Paragraph IV challenges are also less central because peginterferon alfa-2b is a biologic rather than a conventional small-molecule drug. The BPCIA framework does not use the same ANDA Paragraph IV mechanism that drives Hatch-Waxman litigation for small molecules.[7]
No major current settlement agreement appears to provide a credible basis for extending the product’s commercial exclusivity. Any historical settlements would have limited relevance unless they specifically delayed a current competitor, which is not the prevailing market condition.
How does peginterferon alfa-2b compare with peginterferon alfa-2a?
| Attribute |
Peginterferon alfa-2b |
Peginterferon alfa-2a |
| Historical brand |
PEG-Intron |
Pegasys |
| Original sponsor |
Schering-Plough, later Merck |
Roche |
| Molecular basis |
Interferon alfa-2b conjugate |
Interferon alfa-2a conjugate |
| Main historical use |
Hepatitis C |
Hepatitis C and hepatitis B |
| Dosing framework |
Weight-based in major HCV use |
More fixed-dose-oriented in many regimens |
| Current HCV relevance |
Very limited |
Very limited |
| Core competitive problem |
DAA substitution |
DAA substitution |
| Current patent value |
Largely exhausted |
Largely exhausted |
Neither product has a realistic path back to its pre-DAA commercial position. Their historical differences matter less now than the common loss of demand for interferon-based therapy.
What is the geographic market outlook?
The United States, Western Europe, Japan, and other high-income markets have largely moved away from peginterferon alfa-2b for hepatitis C. Residual demand is more plausible in:
- Countries with restricted DAA reimbursement.
- Public-health systems using older treatment protocols.
- Markets with intermittent DAA supply.
- Specialty oncology settings.
- Countries where local manufacturing or tender procurement favors interferon products.
The most relevant commercial variable outside the United States is not patent protection. It is whether health systems can fund and reliably supply direct-acting antivirals.
Key Takeaways
- Peginterferon alfa-2b is a mature biologic with sharply declining commercial value.
- Direct-acting antivirals, not generic competition, caused the principal market collapse.
- PEG-Intron’s original patent and regulatory exclusivity are no longer meaningful market barriers.
- The U.S. hepatitis C market does not support a return to historical revenue levels.
- Biosimilar risk exists but is constrained by limited demand and high manufacturing costs.
- Remaining value is concentrated in regional markets, legacy supply, and narrow oncology use.
- Besremi, ropeginterferon alfa-2b, is a separate product and should not be included in PEG-Intron revenue analysis.
- Financial disclosures do not provide a dependable standalone current revenue figure for peginterferon alfa-2b.
- The remaining competitive moat is manufacturing capability and regulatory execution, not patent exclusivity.
FAQs
Is peginterferon alfa-2b still a first-line hepatitis C treatment?
No. Direct-acting antiviral regimens have replaced interferon-based therapy as the standard first-line approach in the United States and most developed markets.
Is PEG-Intron the same drug as Besremi?
No. PEG-Intron contains peginterferon alfa-2b, while Besremi contains ropeginterferon alfa-2b. They have different molecular structures, indications, labels, and commercial strategies.
Can a company launch a generic version of peginterferon alfa-2b?
A conventional small-molecule generic is not the relevant pathway. A competing sponsor would generally need to pursue a biologic or biosimilar regulatory pathway and demonstrate adequate product quality and clinical similarity.
Does peginterferon alfa-2b have meaningful patent protection in 2025?
Its original composition, therapeutic-use, and core formulation protections are not expected to provide a material current exclusionary barrier. Manufacturing and regulatory requirements remain more important.
Could peginterferon alfa-2b regain commercial value through oncology?
A meaningful recovery would require a new approved indication with clear clinical differentiation. Existing market conditions do not support a return to the product’s historical hepatitis C revenue profile.
References
- U.S. Food and Drug Administration. (2001). PEG-Intron prescribing information.
- U.S. Food and Drug Administration. (2011). Sylatron prescribing information.
- Merck & Co., Inc. (2015). 2014 annual report.
- Merck & Co., Inc. (2018). 2017 annual report.
- U.S. Food and Drug Administration. (2021). Besremi prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
